Details
| Original language | English |
|---|---|
| Pages (from-to) | 12-23 |
| Number of pages | 12 |
| Journal | Prostaglandins Leukotrienes and Essential Fatty Acids |
| Volume | 115 |
| Early online date | 12 Oct 2016 |
| Publication status | Published - Dec 2016 |
Abstract
Introduction Polyunsaturated fatty acids (PUFA) are metabolized in a complex network of elongation, desaturation and beta oxidation. Material and methods The short (1 and 3 wk), and long term (6 and 12 wk) effect of 1076 mg/d docosahexaenoic acid (DHA, free of eicosapentaenoic acid (EPA)) on (absolute) PUFA concentrations in plasma and red blood cells (RBC) of 12 healthy men (mean age 25.1±1.5 years) was investigated. Results RBC DHA concentrations significantly (p<0.001) increased from 28±1.6 µg/mL to 38±2.0 µg/mL (wk 1), 52±3.3 µg/mL (wk 3), 68±2.6 µg/mL (wk 6), and 79±3.5 µg/mL (wk 12). Arachidonic acid (AA) concentrations declined in response to DHA treatment, while the effect was more pronounced in plasma (wk 0: 183±9.9 µg/mL, wk 12: 139±8.0 µg/mL, −24%, p<0.001) compared to RBC (wk 0: 130±3.7 µg/mL, wk 12: 108±4.0 µg/mL, −16%, p=0.001). Furthermore, an increase of EPA concentrations in plasma (wk 0: 15±1.5 µg/mL, wk 1:19±1.6 µg/mL, wk 3: 27±2.3 µg/mL, wk 6: 23±1.2 µg/mL, wk 12: 25±1.7 µg/mL, p<0.001) and RBC (wk 0: 4.7±0.33 µg/mL, wk 1: 6.7±1.3 µg/mL, wk 3: 8.0±0.66 µg/mL, wk 6: 6.9±0.44 µg/mL, wk 12: 6.7±0.45 µg/mL, n.s.) was observed suggesting a retroconversion of DHA to EPA. Conclusion Based on PUFA concentrations we showed that DHA supplementation results in increased EPA levels, whereas it is not known if this impacts the formation of EPA-derived lipid mediators. Furthermore, shifts in the entire PUFA pattern after supplementation of EPA or DHA should be taken into account when discussing differential physiological effects of EPA and DHA.
Keywords
- Adult, Dietary Supplements, Docosahexaenoic Acids/administration & dosage, Drug Administration Schedule, Eicosapentaenoic Acid/blood, Erythrocytes/chemistry, Fatty Acids, Unsaturated/blood, Healthy Volunteers, Humans, Male, Plasma/chemistry, Young Adult, Retroconversion, Purified DHA, LC n3 PUFA, Metabolism, EPA
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Clinical Biochemistry
- Biochemistry, Genetics and Molecular Biology(all)
- Cell Biology
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 115, 12.2016, p. 12-23.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Effects of docosahexaenoic acid supplementation on PUFA levels in red blood cells and plasma
AU - Schuchardt, Jan Philipp
AU - Ostermann, Annika I
AU - Stork, Lisa
AU - Kutzner, Laura
AU - Kohrs, Heike
AU - Greupner, Theresa
AU - Hahn, Andreas
AU - Schebb, Nils Helge
N1 - Funding Information: This study was supported by grants from the German Research Foundation (Grant SCHE 1801 and SCHU 2516) to NHS and JPS. The provision of the DHASCO® oil capsules by DSM Nutritional Products (Columbia, MD, USA) is kindly acknowledged. We would like to thank the participants who contributed their time to this project.
PY - 2016/12
Y1 - 2016/12
N2 - Introduction Polyunsaturated fatty acids (PUFA) are metabolized in a complex network of elongation, desaturation and beta oxidation. Material and methods The short (1 and 3 wk), and long term (6 and 12 wk) effect of 1076 mg/d docosahexaenoic acid (DHA, free of eicosapentaenoic acid (EPA)) on (absolute) PUFA concentrations in plasma and red blood cells (RBC) of 12 healthy men (mean age 25.1±1.5 years) was investigated. Results RBC DHA concentrations significantly (p<0.001) increased from 28±1.6 µg/mL to 38±2.0 µg/mL (wk 1), 52±3.3 µg/mL (wk 3), 68±2.6 µg/mL (wk 6), and 79±3.5 µg/mL (wk 12). Arachidonic acid (AA) concentrations declined in response to DHA treatment, while the effect was more pronounced in plasma (wk 0: 183±9.9 µg/mL, wk 12: 139±8.0 µg/mL, −24%, p<0.001) compared to RBC (wk 0: 130±3.7 µg/mL, wk 12: 108±4.0 µg/mL, −16%, p=0.001). Furthermore, an increase of EPA concentrations in plasma (wk 0: 15±1.5 µg/mL, wk 1:19±1.6 µg/mL, wk 3: 27±2.3 µg/mL, wk 6: 23±1.2 µg/mL, wk 12: 25±1.7 µg/mL, p<0.001) and RBC (wk 0: 4.7±0.33 µg/mL, wk 1: 6.7±1.3 µg/mL, wk 3: 8.0±0.66 µg/mL, wk 6: 6.9±0.44 µg/mL, wk 12: 6.7±0.45 µg/mL, n.s.) was observed suggesting a retroconversion of DHA to EPA. Conclusion Based on PUFA concentrations we showed that DHA supplementation results in increased EPA levels, whereas it is not known if this impacts the formation of EPA-derived lipid mediators. Furthermore, shifts in the entire PUFA pattern after supplementation of EPA or DHA should be taken into account when discussing differential physiological effects of EPA and DHA.
AB - Introduction Polyunsaturated fatty acids (PUFA) are metabolized in a complex network of elongation, desaturation and beta oxidation. Material and methods The short (1 and 3 wk), and long term (6 and 12 wk) effect of 1076 mg/d docosahexaenoic acid (DHA, free of eicosapentaenoic acid (EPA)) on (absolute) PUFA concentrations in plasma and red blood cells (RBC) of 12 healthy men (mean age 25.1±1.5 years) was investigated. Results RBC DHA concentrations significantly (p<0.001) increased from 28±1.6 µg/mL to 38±2.0 µg/mL (wk 1), 52±3.3 µg/mL (wk 3), 68±2.6 µg/mL (wk 6), and 79±3.5 µg/mL (wk 12). Arachidonic acid (AA) concentrations declined in response to DHA treatment, while the effect was more pronounced in plasma (wk 0: 183±9.9 µg/mL, wk 12: 139±8.0 µg/mL, −24%, p<0.001) compared to RBC (wk 0: 130±3.7 µg/mL, wk 12: 108±4.0 µg/mL, −16%, p=0.001). Furthermore, an increase of EPA concentrations in plasma (wk 0: 15±1.5 µg/mL, wk 1:19±1.6 µg/mL, wk 3: 27±2.3 µg/mL, wk 6: 23±1.2 µg/mL, wk 12: 25±1.7 µg/mL, p<0.001) and RBC (wk 0: 4.7±0.33 µg/mL, wk 1: 6.7±1.3 µg/mL, wk 3: 8.0±0.66 µg/mL, wk 6: 6.9±0.44 µg/mL, wk 12: 6.7±0.45 µg/mL, n.s.) was observed suggesting a retroconversion of DHA to EPA. Conclusion Based on PUFA concentrations we showed that DHA supplementation results in increased EPA levels, whereas it is not known if this impacts the formation of EPA-derived lipid mediators. Furthermore, shifts in the entire PUFA pattern after supplementation of EPA or DHA should be taken into account when discussing differential physiological effects of EPA and DHA.
KW - Adult
KW - Dietary Supplements
KW - Docosahexaenoic Acids/administration & dosage
KW - Drug Administration Schedule
KW - Eicosapentaenoic Acid/blood
KW - Erythrocytes/chemistry
KW - Fatty Acids, Unsaturated/blood
KW - Healthy Volunteers
KW - Humans
KW - Male
KW - Plasma/chemistry
KW - Young Adult
KW - Retroconversion
KW - Purified DHA
KW - LC n3 PUFA
KW - Metabolism
KW - EPA
UR - http://www.scopus.com/inward/record.url?scp=84992028032&partnerID=8YFLogxK
U2 - 10.1016/j.plefa.2016.10.005
DO - 10.1016/j.plefa.2016.10.005
M3 - Article
C2 - 27914509
VL - 115
SP - 12
EP - 23
JO - Prostaglandins Leukotrienes and Essential Fatty Acids
JF - Prostaglandins Leukotrienes and Essential Fatty Acids
SN - 0952-3278
ER -